Clinical Trial Detail

NCT ID NCT03013998
Title Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Beat AML, LLC
Indications

acute myeloid leukemia

Therapies

Azacitidine + Enasidenib

Azacitidine + Entospletinib

Cytarabine + Daunorubicin + Samalizumab

Azacitidine + BI 836858

Age Groups: adult senior

No variant requirements are available.